evok longas you see in the chart it seems there is Adam and Eve pattern if evok broken 3.5 in high volume . hope will seebig jump to around7.5$
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−11.09 USD
−7.79 M USD
5.18 M USD
1.36 M
About Evoke Pharma, Inc.
Sector
CEO
Matthew J. D'Onofrio
Headquarters
Solana Beach
Website
Founded
2007
FIGI
BBG0026ZG0X7
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
Evoke Pharma gone Woke. EVOKThese pharma stocks are dropping like flies.
Immediate targets 0.29, 0.16. Invalidation at 0.83
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci g
EVOK LongPrice above SMA13
OBV>OBV34
WR > -80
Entry 1.4
Stop 1
Target 3.7
Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader. I trade option to test my trading plan with small cost.
EVOK (NASDAQ) - Wait and SeeGreetings
Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, feel free to send us message (inbox).
Pra Trading :
- Please care for Money Management
- Have a goo
EVOK: Goes up when everything else goes down...EVOK has an analyst sell target at $10. I believe that with a float of 24M, this stock has the stock characteristics to hit $10 and maybe even further. And why is it positive when everything else is down???
$EVOK- Evoke Pharma IncWOW, looks pretty cool. Do I want it though, not right now, no...
Its starting to build up is how I look at it. From 3.75 to 4.15 is amazing buying power for you to actually make some AMAZING gains....
Invest Smart
Can't predict the future but it looks promising...
FDA Approves Evoke’s GIMOTI™We are extremely pleased to have received FDA approval to commercially market GIMOTI in the United States. This approval represents the first novel pharmaceutical treatment for gastroparesis in several decades. We are excited to be able to offer health care providers and their patients a unique non-
FDA Approves Evoke’s GIMOTI™!!!EVOK: Evoke Pharma, Inc.
2020-06-19 15:32:10
FDA Approves Evoke’s GIMOTI™
EVOK - MA200 Holding - Momentum IncreasingEvoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis
Unusual Accumulation in EVOKE PHARMA INC. Keep watchKeep on your watchlist for continuation in price action and buy side volume, looks like accumulation is underway and the fact it is a Pharmaceutical stock, Trial data or FDA releases could be the stimulus.
Very speculative, but very rewarding trade setup on the chart.
COMPANY PROFILE
Evoke Pharm
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of EVOK is 4.33 USD — it has decreased by −3.78% in the past 24 hours. Watch Evoke Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Evoke Pharma, Inc. stocks are traded under the ticker EVOK.
EVOK stock has fallen by −1.59% compared to the previous week, the month change is a −16.81% fall, over the last year Evoke Pharma, Inc. has showed a −71.13% decrease.
We've gathered analysts' opinions on Evoke Pharma, Inc. future price: according to them, EVOK price has a max estimate of 18.00 USD and a min estimate of 18.00 USD. Watch EVOK chart and read a more detailed Evoke Pharma, Inc. stock forecast: see what analysts think of Evoke Pharma, Inc. and suggest that you do with its stocks.
EVOK reached its all-time high on Oct 7, 2013 with the price of 2,052.82 USD, and its all-time low was 3.54 USD and was reached on Sep 5, 2024. View more price dynamics on EVOK chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
EVOK stock is 6.22% volatile and has beta coefficient of 1.41. Track Evoke Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Evoke Pharma, Inc. there?
Today Evoke Pharma, Inc. has the market capitalization of 6.43 M, it has decreased by −1.75% over the last week.
Yes, you can track Evoke Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
Evoke Pharma, Inc. is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
EVOK earnings for the last quarter are −0.94 USD per share, whereas the estimation was −0.38 USD resulting in a −147.37% surprise. The estimated earnings for the next quarter are −0.63 USD per share. See more details about Evoke Pharma, Inc. earnings.
Evoke Pharma, Inc. revenue for the last quarter amounts to 2.65 M USD, despite the estimated figure of 3.36 M USD. In the next quarter, revenue is expected to reach 3.08 M USD.
EVOK net income for the last quarter is −1.31 M USD, while the quarter before that showed −1.27 M USD of net income which accounts for −3.56% change. Track more Evoke Pharma, Inc. financial stats to get the full picture.
No, EVOK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 4.00 employees. See our rating of the largest employees — is Evoke Pharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Evoke Pharma, Inc. EBITDA is −5.90 M USD, and current EBITDA margin is −143.44%. See more stats in Evoke Pharma, Inc. financial statements.
Like other stocks, EVOK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Evoke Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Evoke Pharma, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Evoke Pharma, Inc. stock shows the sell signal. See more of Evoke Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.